Literature DB >> 8396232

The reliability of serological tests for the diagnosis of genital herpes: a critique.

P R Field1, D W Ho, W L Irving, D Isaacs, A L Cunningham.   

Abstract

The reliability and limitations of the currently used routine tests for herpes simplex virus type 2 (HSV-2) antibody in Australia are reviewed. Six case reports illustrate the clinical dangers of overinterpretation of the currently available kits and the need for a readily available specific HSV-2 antibody test. In Sydney, HSV-2 causes approximately 85% of primary genital herpes and > 95% of recurrent genital herpes. Due to the extensive serological cross-reactivity between HSV-1 and HSV-2, currently available "type specific" commercial assays cannot reliably distinguish between the 2. Isolation of herpes simplex virus (HSV) or detection of HSV antigen in vesicle fluid is the preferred diagnostic test but may be overlooked or patients may have no visible lesions. The only accurate techniques for detecting HSV-2 specific antibody are the Western blot assay and an enzymatic immunoassay using glycoprotein G (gG-2), a component of the HSV-2 envelope. These tests, which still are restricted to research laboratories can be used to accurately identify people with previous exposure to HSV-2 (IgG) or to diagnose primary infection where virus isolation has not been performed or is impossible. Current commercially available antibody tests may have extensive cross-reactivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8396232     DOI: 10.3109/00313029309084794

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Evaluation of three glycoprotein G2-based enzyme immunoassays for detection of antibodies to herpes simplex virus type 2 in human sera.

Authors:  A M Eis-Hübinger; M Däumer; B Matz; K E Schneweis
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

4.  An evaluation of near patient tests for detecting herpes simplex virus type-2 antibody.

Authors:  M Saville; D Brown; C Burgess; K Perry; S Barton; F Cowan; G Palu; C Mengoli
Journal:  Sex Transm Infect       Date:  2000-10       Impact factor: 3.519

5.  Peptide sequences of glycoprotein G-2 discriminate between herpes simplex virus type 2 (HSV-2) and HSV-1 antibodies.

Authors:  M Levi; U Rudén; B Wahren
Journal:  Clin Diagn Lab Immunol       Date:  1996-05

6.  Clinical and epidemiological features of acute follicular conjunctivitis with special reference to that caused by herpes simplex virus type 1.

Authors:  E Uchio; S Takeuchi; N Itoh; N Matsuura; S Ohno; K Aoki
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

7.  Gender-dependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D.

Authors:  Xiuli Zhang; Florence A Castelli; Xiaoming Zhu; Michele Wu; Bernard Maillère; Lbachir BenMohamed
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

8.  Detection of immunoglobulin M antibodies to glycoprotein G-2 by western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections.

Authors:  D W Ho; P R Field; W L Irving; D R Packham; A L Cunningham
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

9.  Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B.

Authors:  Aziz Alami Chentoufi; Nicholas R Binder; Noureddine Berka; Guillaume Durand; Alex Nguyen; Ilham Bettahi; Bernard Maillère; Lbachir BenMohamed
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.